Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro.
V F Tapson, … , D M Center, J S Berman
V F Tapson, … , D M Center, J S Berman
Published September 1, 1988
Citation Information: J Clin Invest. 1988;82(3):950-957. https://doi.org/10.1172/JCI113703.
View: Text | PDF
Research Article

Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro.

  • Text
  • PDF
Abstract

Growth factor receptors for T lymphocytes, such as interleukin 2 and insulin, are present on activated but not resting T lymphocytes. We sought to determine if insulin-like growth factor I (IGF-I) could act as a growth factor for human T cells and to characterize its receptor on resting and activated cells. Recombinant IGF-I induced two separate functions. It was chemotactic for and increased incorporation of tritiated thymidine into both unactivated (resting) and mitogen-activated T cells. High-affinity 125I-IGF-I binding to human T cells was saturable with an apparent Kd of 1.2 +/- .6 X 10(-10) M for binding to activated T cells and 1.2 +/- .9 X 10(-10) for unactivated T cells. The calculated binding for activated cells was 330 +/- 90 and for resting cells 45 +/- 9 high-affinity receptor sites per cell. Affinity cross-linking of 125I-IGF-I to resting or activated T cells revealed a radioligand-receptor complex of 360,000 mol wt when analyzed by SDS-PAGE without reduction and complexes of 270,000 and 135,000 mol wt upon reduction; prior incubation with excess unlabeled IGF-I prevented formation of the 125I-IGF-I receptor complex. Our data suggest that both resting and activated T lymphocytes bear functional IGF-I receptors similar to those found in other tissues. These receptors may mediate T cell growth and chemotaxis.

Authors

V F Tapson, M Boni-Schnetzler, P F Pilch, D M Center, J S Berman

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts